Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Intellia Therapeutics (NTLA)
NASDAQ:NTLA
RESEARCH TOOLSreports
NTLA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$8.96 - $34.87
Previous CloseN/A
Volume723.92K
Average Volume (3M)3.21M
Market Cap
$1.17B
Enterprise Value$1.52B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta3.01
Next Earnings
Feb 20, 2025EPS Estimate
-1.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.45
Shares Outstanding101,848,570
10 Day Avg. Volume3,293,482
30 Day Avg. Volume3,207,369
Standard Deviation0.24
R-Squared0.15
Alpha-0.00018
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)27.26
Price to Cash Flow (P/CF)-3.50
P/FCF Ratio0.00
Enterprise Value/Market Cap1.29
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit55.65
Enterprise Value/Ebitda-2.88
Forecast
1Y Price Target
$40.08Price Target Upside226.38% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
---
Bulls Say, Bears Say
Bulls Say
Financial StabilityWorkforce reduction and cash runway extension will extend the company's financial stability into 2027.
Gene Editing ProgressSwift enrollment in Phase 3 for ATTR-CM is seen as a promising sign of patient acceptance of gene editing.
Safety And Efficacy Of Nex-zNex-z continues to appear well-tolerated with mild and transient treatment-related liver enzyme elevations and mild decreases in thyroxine levels, indicating optimism on long-term safety.
Bears Say
Cross-trial Comparison ChallengesCross-trial comparison of nex-z efficacy is complicated by significant differences in baseline patient severity.
Pipeline ConcernsThe stock could be weak as a result of this update since there's no longer a meaningful potential pipeline catalyst this year.
Program DiscontinuationDiscontinuation of the AATD-lung program aims to focus resources on more promising areas.
---
Ownership Overview
1.69% Insiders
20.55% Mutual Funds
35.12% Other Institutional Investors
11.66% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NTLA FAQ
What was Intellia Therapeutics’s price range in the past 12 months?
Intellia Therapeutics lowest stock price was $8.96 and its highest was $34.87 in the past 12 months.
What is Intellia Therapeutics’s market cap?
Intellia Therapeutics’s market cap is $1.17B.
When is Intellia Therapeutics’s upcoming earnings report date?
Intellia Therapeutics’s upcoming earnings report date is Feb 20, 2025 which is yesterday.
How were Intellia Therapeutics’s earnings last quarter?
Intellia Therapeutics released its earnings results on Nov 07, 2024. The company reported -$1.34 earnings per share for the quarter, beating the consensus estimate of -$1.39 by $0.05.
Is Intellia Therapeutics overvalued?
According to Wall Street analysts Intellia Therapeutics’s price is currently Undervalued.
Does Intellia Therapeutics pay dividends?
Intellia Therapeutics does not currently pay dividends.
What is Intellia Therapeutics’s EPS estimate?
Intellia Therapeutics’s EPS estimate is -1.32.
How many shares outstanding does Intellia Therapeutics have?
Intellia Therapeutics has 101,848,570 shares outstanding.
What happened to Intellia Therapeutics’s price movement after its last earnings report?
Intellia Therapeutics reported an EPS of -$1.34 in its last earnings report, beating expectations of -$1.39. Following the earnings report the stock price went down -0.374%.
Which hedge fund is a major shareholder of Intellia Therapeutics?
Currently, no hedge funds are holding shares in NTLA
---
Intellia Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$40.08 (226.38% Upside)
$40.08 (226.38% Upside)
Blogger Sentiment
Bullish
NTLA Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 280.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $824.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 1.0%
Last 30 Days ▼ 1.1%
Last 30 Days ▼ 1.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-55.73%
12-Months-Change
Fundamentals
Return on Equity
-54.26%
Trailing 12-Months
Asset Growth
-5.63%
Trailing 12-Months
Company Description
Intellia Therapeutics
Intellia Therapeutics, Inc. engages in the development of gene editing-based therapies. It provides scientific expertise, clinical development, and intellectual property position to unlock broad therapeutic applications of CRISPR or Cas9 genome editing and develop a potential new drug class. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.
---
NTLA Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented significant progress in Intellia's clinical pipeline and financial management, with notable achievements in CRISPR-based treatments and regulatory clearances. However, challenges such as decreased collaboration revenue and increased operational expenses were also highlighted.Read More>---
NTLA Revenue Breakdown
100.00% Collaboration revenue
---
NTLA Stock 12 Month Forecast
Average Price Target
$40.08
▲(226.38% Upside)
Technical Analysis
Arcturus Therapeutics
―
Editas Medicine
―
Crispr Therapeutics AG
―
Beam Therapeutics
―
Verve Therapeutics
―
Best Analysts Covering NTLA
1 Year
1 Year Success Rate
13/38 ratings generated profit
1 Year Average Return
+85.39%
reiterated a buy rating 3 months ago
Copying Geulah Livshits's trades and holding each position for 1 Year would result in 34.21% of your transactions generating a profit, with an average return of +85.39% per trade.
---